Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

// request.cf · coarse context

A page that knows where it met you.

Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.

Country
US
Cloudflare location
CMH
Connection
HTTP/2
Language
Not provided

Ray ID: a222bce69a7ccf57

Jump to content

Talk:CD19

Page contents not supported in other languages.
Add topic
From Wikipedia, the free encyclopedia
Latest comment: 13 years ago by Rod57 in topic Use as immunoconjugate target

Untitled

[edit]

DFAS —Preceding unsigned comment added by 128.192.23.183 (talk) 17:52, 11 August 2008 (UTC)Reply

I think something should be mentioned about the use of CD19 as a B cell neoplasm target (most recently as a target for CAR-modified T cells in CLL cf http://www.ncbi.nlm.nih.gov/pubmed/21830940 ) Ulalume (talk) 18:14, 3 November 2011 (UTC)Reply

Use as immunoconjugate target

[edit]

eg in B43-genistein, an anti-CD19 antibody linked to genistein eg for leukemia. : Chen; et al. (1999). "Clinical pharmacokinetics of the CD19 receptor-directed tyrosine kinase inhibitor B43-Genistein in patients with B-lineage lymphoid malignancies". {{cite journal}}: Cite journal requires |journal= (help); Explicit use of et al. in: |author= (help) - Rod57 (talk) 00:03, 10 June 2013 (UTC)Reply